By a News Reporter-Staff News Editor at Clinical Trials Week -- Current study results on Diabetes have been published. According to news reporting out of Baltimore, Maryland, by NewsRx editors, research stated, "The efficacy of homocysteine-lowering therapy with folic acid to lower homocysteine levels in an effort to reduce cardiovascular disease (CVD) risk in patients with kidney disease remains inconclusive. We conducted a meta-analysis of relevant randomized trials to further examine this issue."
Our news journalists obtained a quote from the research from Johns Hopkins University, "This meta-analysis included 8234 patients with kidney disease from nine qualified randomized trials using folic acid therapy, and with CVD reported as one of the endpoints. Relative risk (RR) was used to measure the effect of folic acid supplementation on risk of CVD using a random effects model. When pooling the nine randomized trials, folic acid therapy reduced the risk of CVD by 10% (RR = 0.90; 95% CI:0.81-1.00, P = 0.046). A greater beneficial effect was observed among those trials without a history of grain fortification with folic acid (0.82; 0.70-0.96, P = 0.01), with lower percent baseline diabetes (<30% (median), 0.80; 0.65-0.99, P = 0.04), and in patients with end-stage renal disease (ESRD) or advanced chronic kidney disease (ACKD) (0.85; 0.77-0.94, P = 0.002). Furthermore, a meta-regression analysis suggested a positive dose-response relationship between percent baseline diabetes and log-RR for CVD risk associated with folic acid supplementation (P = 0.007). Most importantly, even the inclusion of three subgroup results did not substantially affect the results (n = 11032, RR: 0.93; 95% CI:0.87-0.99, P = 0.03)."
According to the news editors, the research concluded: "Our meta-analysis indicates that folic acid supplementation may be effective for CVD prevention in patients with kidney disease, particularly in trials among patients without a history of grain fortification with folic acid, with lower percent baseline diabetes, and in patients with ESRD or ACKD."
For more information on this research see: Homocysteine-lowering therapy with folic acid is effective in cardiovascular disease prevention in patients with kidney disease: A meta-analysis of randomized controlled trials. Clinical Nutrition, 2013;32(5):722-727. Clinical Nutrition can be contacted at: Churchill Livingstone, Journal Production Dept, Robert Stevenson House, 1-3 Baxters Place, Leith Walk, Edinburgh EH1 3AF, Midlothian, Scotland. (Elsevier - www.elsevier.com; Clinical Nutrition - www.elsevier.com/wps/product/cws_home/623017)
Our news journalists report that additional information may be obtained by contacting X.H. Qin, Johns Hopkins University, Center Early Life Origins Dis, Bloomberg Sch Public Hlth, Dept. of Populat Family & Reprod Hlth, Baltimore, MD 21205, United States. Additional authors for this research include Y. Huo, D. Xie, F.F. Hou, X.P. Xu and X.B. Wang (see also Diabetes).
Keywords for this news article include: Therapy, Maryland, Diabetes, Baltimore, Cardiology, Homocysteine, United States, Sulfur Amino Acids, Cardiovascular Diseases, North and Central America, Clinical Trials and Studies
Our reports deliver fact-based news of research and discoveries from around the world. Copyright 2013, NewsRx LLC
To see more of the NewsRx.com, or to subscribe, go to http://www.newsrx.com .
Articles featured in Life Extension Daily News are derived from a variety of news sources and are provided as a service by Life Extension. These articles, while of potential interest to readers of Life Extension Daily News, do not necessarily represent the opinions nor constitute the advice of Life Extension.